# TinyGemsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Receives FDA Fast Track Designation for CLD-201 in Soft Tissue Sarcoma

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing targeted genetic medicine delivery therapies, announced that the U.S. Food and Drug Administration granted Fast Track designation to CLD-201 (SuperNova), its allogeneic adipose stem-cell loaded oncolytic virus for treating soft tissue sarcoma. The designation provides opportunities for expedited development, including priority review and accelerated approval. CLD-201, which received IND clearance in April, will enter a Phase 1 trial evaluating safety and efficacy in sarcoma, triple-negative breast cancer, and head and neck squamous cell carcinoma. Chief Medical Officer Guy Travis Clifton, M.D., said the milestone validates CLD-201’s potential to deliver durable, transformational treatment for patients with advanced tumors.

 To view the full press release, visit: https://ibn.fm/P5fNx

 About Calidi Biotherapeutics

 Calidi Biotherapeutics is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi’s novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi’s preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, visit the company’s website at www.calidibio.com .

 NOTE TO INVESTORS: The latest news and updates relating to CLDI are available in the company’s newsroom at https://ibn.fm/CLDI

 About TinyGems

 TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.TinyGems.com

 Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

 TinyGemsAustin, Texaswww.TinyGems.com512.354.7000 OfficeEditor@TinyGems.com

 TinyGems is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/tg/tinygemsbreaks-calidi-biotherapeutics-inc-nyse-american-cldi-receives-fda-fast-track-designation-for-cld-201-in-soft-tissue-sarcoma/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/calidi-biotherapeutics-cld-201-receives-fda-fast-track-for-sarcoma-treatment/3e0536055b3c13cac85e4b25ec8d9e39) 


Pickup - [https://burstable.news/news](https://burstable.news/news/202507/124517-calidi-biotherapeutics-inc-receives-fda-fast-track-designation-for-cld-201-in-soft-tissue-sarcoma)

Pickup - [https://faqstaq.news/news](https://faqstaq.news/news/202507/124644-faq-on-calidi-biotherapeutics-inc-receiving-fda-fast-track-designation-for-cld-201-in-soft-tissue-sarcoma)

Pickup - [https://goinvest.com/ibn-faqstaq](https://goinvest.com/ibn-faqstaq/202507/124583-faq-on-calidi-biotherapeutics-incs-fda-fast-track-designation-for-cld-201-in-soft-tissue-sarcoma)
 



[Reddit Post](https://www.reddit.com/r/technology_press/comments/1mcgzto/calidi_biotherapeutics_cld201_receives_fda_fast/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/257/29/oxenuCux.webp)